Skip to main content
Newbury Pharmaceuticals AB logo

Newbury Pharmaceuticals AB — Investor Relations & Filings

Ticker · NEWBRY ISIN · SE0015244884 LEI · 549300F7XHU3I8CWL373 ST Manufacturing
Open in API
Filings indexed 2 across all filing types
Latest filing 2018-10-05 Regulatory Filings
Country SE Sweden
Listing ST NEWBRY

About Newbury Pharmaceuticals AB

https://www.newburypharma.com/

Newbury Pharmaceuticals AB is a hybrid pharmaceutical company focused on specialty prescription drugs and branded medicines. The company's business model combines the capabilities of a marketing authorization holder with those of a specialized commercial partner. It builds its portfolio through global partnerships, in-licensing products, and acting as an exclusive distributor and local representative for other brands. The primary market focus is the Nordic region, with selective international sales. The product portfolio covers various therapeutic areas, including oncology and rare diseases. Newbury Pharmaceuticals manages the full commercialization process, including regulatory affairs, market access, supply chain, and marketing, to deliver medicines to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Edison Investment Research Limited: Edison issues outlook on NeuroVive Pharmaceutical (NVP)
Regulatory Filings Classification · 99% confidence The document is a brief announcement from Edison Investment Research regarding NeuroVive Pharmaceutical, dated October 5, 2018. It summarizes recent corporate activities (licensing deal, clinical trial updates) and provides an updated valuation. Crucially, the text ends with a link stating, "[Click here] to view the full report," and mentions that "All reports published by Edison are available to download free of charge from its website." This structure indicates that the provided text is an announcement *about* a research report, not the full report itself. Since it is an announcement regarding investment research/analysis, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory news dissemination, or potentially an Investor Presentation (IP) if the full document was a presentation, but given the context of an external research firm publishing an 'outlook' and directing users to download the 'full report', RNS is the most appropriate general classification for this type of market news release, especially when the document length is short (4268 chars) and points to a separate, full document (Menu vs Meal Rule).
2018-10-05 English
EQS-News: Edison Investment Research Limited: Edison issues initiation on NeuroVive Pharmaceutical (NVP)
Report Publication Announcement Classification · 99% confidence The document is an announcement from 'Edison Investment Research Limited' titled 'Edison issues initiation on NeuroVive Pharmaceutical (NVP)'. It summarizes key findings, valuation (SEK1.5bn), and near-term events related to the company's drug pipeline. Crucially, it contains the phrase '[Click here] to view the full report' and states that 'All reports published by Edison are available to download free of charge from its website'. This structure indicates that the current document is an announcement or summary *of* a research report, not the full report itself. Since the document is a summary/initiation report from an external research firm, it does not fit neatly into standard SEC filings (10-K, ER, IR). It is best classified as an Investor Presentation (IP) if it were the full deck, but given it is an announcement pointing to a full report, and it discusses investment analysis, it aligns most closely with the general category of investor-focused materials. However, looking at the definitions, 'Investor Presentation (IP)' is for detailed presentations. This is an 'initiation' report summary. Since it is an announcement about research, and research reports often fall under Investor Information, the closest fit among the provided options for an external research initiation summary that points to a full document is often categorized under general investor communications. Given the options, and the fact that it is an announcement about research/analysis, it is most similar in nature to an Investor Presentation (IP) or a general Regulatory Filing (RNS) if it were not for the specific content. Since it is an announcement *about* research, and the document length is short (4599 chars), it strongly suggests an RPA or RNS based on Rule 2. However, the content is substantive research analysis. If we must choose a content-based classification, 'Investor Presentation (IP)' covers detailed analysis for investors. If we strictly follow Rule 2 (Menu vs Meal), it should be RPA or RNS. Since it is an announcement of a research report, and 'Research Update' is listed as a keyword, it is a notification about published research. I will classify it as a Report Publication Announcement (RPA) because it announces the publication of the full Edison report and provides a link, adhering to Rule 2, even though the content is research-heavy.
2017-06-29 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.